London, UK; Brentwood, TN, US: 9 February 2007 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, announces that the following 6 monthly block listing return in
respect of the Company's 6% unsecured convertible loan notes has been lodged
with the FSA today, in accordance with Listing Rule 3.5.6.
